Lysine acetylations are reversible posttranslational modifications of histone and nonhistone proteins that play important regulatory roles in signal transduction cascades and gene expression. Lysine acetylations are regulated by histone acetyltransferases as writers and histone deacetylases as erasers. Because of their role in signal transduction cascades, these enzymes are important players in inflammation. Therefore, histone acetyltransferase inhibitors could reduce inflammatory responses. Among the few histone acetyltransferase inhibitors described, C646 is one of the most potent (K i of 0.4 μM for the histone acetyltransferase p300). C646 was described to affect the NF-κB pathway; an important pathway in inflammatory responses, which is regulated by acetylation. This pathway has been implicated in asthma and COPD. Therefore, we hypothesized that via regulation of the NF-κB signaling pathway, C646 can inhibit pro-inflammatory gene expression, and have potential for the treatment of inflammatory lung diseases. In line with this, we demonstrate here that C646 reduces pro-inflammatory gene expression in RAW264.7 murine macrophages and murine precision-cut lung slices. To unravel its effects on cellular substrates we applied mass spectrometry and found, counterintuitively, a slight increase in acetylation of histone H3. Based on this finding, and structural features of C646, we presumed inhibitory activity of C646 on histone deacetylases, and indeed found inhibition of histone deacetylases from 7 μM and higher concentrations. This indicates that C646 has potential for further development towards applications in the treatment of inflammation, however, its newly discovered lack of selectivity at higher concentrations needs to be taken into account. C646 33
Introduction
Lysine acetylations are reversible posttranslational modifications that frequently occur on histones and other cellular proteins. These modifications have been recognized to play important regulatory roles in signal transduction cascades and gene expression (1) (2) .
Protein lysine acetylations are regulated by histone acetyltransferases (HATs) as writers and histone deacetylases (HDACs) as erasers. In the past decades many different isoforms of HATs and HDACs have been discovered (3) (4), and aberrations in their activity have been associated with diseases such as inflammatory disorders or cancer (5) (6) .
For this reason, the development of small molecule inhibitors of these enzymes and their applications in therapeutic areas, such as the treatment of inflammatory diseases, have received considerable attention. This has resulted in the development of small molecule HAT inhibitors (HATi) (7) . Virtual screening enabled the identification of the small molecule inhibitor C646 as a potent and cell-permeable p300 HATi (K i 0.4 μM) which is selective for p300 among HAT isoenzymes such as PCAF, GCN5 and MOZ (8) .
C646 has shown interesting effects in disease models. For example, C646 has successfully been applied in an animal model of neuropathic pain. C646 was administered in rats via a lumbar intrathecal catheter, demonstrating the feasibility of local administration of C646 in animals. It was found that C646 treatment diminished both the p300 promoter binding and the expression of COX-2 (9) . In another study on prostate cancer cell lines it was found that C646-mediated inhibition of p300 increased apoptosis, which was, among others, caused by inhibition of the androgen receptor and the NF-κB pathway (10) . These studies indicate that C646 influences signaling cascades such as the NF-κB pathway.
The effects of C646 on the NF-κB pathway could be explained by the role for p300 that has been described in the regulation of the NF-κB pathway (5) . For instance, acetylations of the p65 NF-κB subunit on lysines 218, 221 and 310 are mediated by the HATs p300 and PCAF (11) and increase transcriptional activity. In contrast, acetylations on lysines 122 and 123 decrease transcriptional activity and are also mediated by p300 (12) . Furthermore, upon DNA binding, the transcriptional activation domain of p65 interacts with the HATs p300 and CBP as co-activators of gene transcription (13) . Thus, p300 plays a crucial role in the regulation of acetylation of specific lysine residues of NF-κB, which then determine NF-κB transcriptional capacity, DNA binding and duration of action.
This suggests that inhibition of the HAT p300 using small molecule inhibitors such as C646 may allow for regulation of gene expression via the NF-κB transcription factor (7) . Since the NF-κB pathway is a key factor in inflammatory responses, this calls for investigation of the potential of C646 to suppress these responses. Of particular interest may be applications in inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease (COPD), which still pose a major health problem. Interestingly, a role for the NF-κB pathway has been described in these diseases, as reviewed (14) . Increased NF-κB activity has been observed in the bronchial epithelium and peripheral blood mononuclear cells of asthmatic patients (15) (16) . Increased nuclear localization of p65 was observed in sputum macrophages during exacerbations of COPD (17) and also in bronchial biopsies of stable COPD patients (18) . Several lines of research have focused on modulating NF-κB activity as a novel therapeutic strategy for the treatment of asthma and COPD (14) .
We hypothesize that pharmacological inhibition of the HAT p300 by the small molecule inhibitor C646 will result in inhibition of pro-inflammatory gene expression via inhibition of the NF-κB signaling pathway.
For these reasons, we set out to explore the p300 HATi C646 in a model system for inflammatory lung diseases. We observed decreased NF-κB reporter gene activity in RAW-Blue murine macrophages, and decreased pro-inflammatory gene expression in RAW264.7 murine macrophages as well as in murine lung tissue slices. Next to this we set out to quantify changes in lysine acetylation in the cellular substrates of p300. Acetylation of histone H3 and histone H4 was quantified using mass spectrometry in RAW264.7 macrophages.
Counterintuitively, C646 increased acetylation on histone H3 residues 18-26, containing H3 K18 and H3 K23. Based on these findings and the structural properties of C646 we investigated its inhibitory potential on recombinant HDACs and found inhibition from 7 μM and higher concentrations for type I and II HDACs. Importantly, these findings call for further optimization of the selectivity profile of the p300 HATi C646 and its derivatives.
Results

C646 inhibits NF-κB activity
First, the viability of RAW264.7 cells treated with C646 at different concentrations was assessed (data not shown). As a reference, the well-studied HDACi SAHA was also included at a single concentration and tested in a viability assay (data not shown). Subsequently, to explore the potential of C646 in suppression of (NF-κB mediated) inflammation, an NF-κB reporter gene assay was employed, using RAW-Blue (modified RAW264.7) macrophages.
For NF-κB activation, LPS and IFNγ were employed as inflammatory stimulus. An LPS and IFNγ stimulus at 10 ng/mL of each for 4 h induced NF-κB activity ( Fig. 1 ). We then proceeded to pre-treatment with C646 at concentrations of 1, 5, 10, 15, 20, 25 and 30 μM for 16 h before receiving the stimulus, rendering a total incubation time with the inhibitor of 20 h. These concentrations were chosen because they are above the K i value for p300 inhibition of 0.4 μM (8) at different folds. Concentrations above 30 μM were not studied due to decreased viability of the macrophages. A total incubation time of 20 h was chosen based on a previous study with a similar incubation time (24 h), where C646 affected the NF-κB pathway (decreased expression levels of p65, and decreased binding of p65 at the IkBa promoter were observed) in a disease model of prostate cancer (10) , suggesting that C646 35 2 effects of C646 on this pathway in cells take place at these relatively long incubation times.
Interestingly, at 15 μM or higher concentrations of C646 treatment, this resulted in significant inhibition of LPS and IFNγ-induced NF-κB promoter activity ( Fig. 1 ). This indicates influence of C646 on the NF-κB pathway. In contrast, pre-treatment with the reference compound SAHA at a concentration of 0.41 μM further enhanced LPS and IFNγinduced NF-κB activity ( Fig. 1 ).
C646 inhibits pro-inflammatory gene expression in RAW264.7 macrophages and precision-cut lung slices
Next, we monitored expression of the NF-κB-mediated pro-inflammatory genes TNFα, iNOS, IL1β, IL12b, IL6, and KC (murine IL8) in RAW264.7 murine macrophages upon receiving the same LPS and IFNγ stimulus, using RT-q-PCR. The stimulus was found to increase expression of all genes (shown for TNFα and IL12b in Fig. 2A and B ; data not shown for the remaining genes), with the exception of KC, which was not expressed in RAW264.7 macrophages. Pre-treatment with C646 resulted in a dose dependent decrease in the LPS and IFNγ-induced expression of TNFα which became significant at 30 μM ( Fig. 2A , Table 1 ). Furthermore, for IL12b, even though a dose-dependent decrease was Table 1 ). The expression of other studied genes remained unchanged (Table 1 ). In contrast, pre-treatment with the reference compound SAHA at 0.41 μM further upregulated LPS and IFNγ-induced gene expression of IL1β (Table 1) , but did not affect the expression of the other studied genes ( Table 1 ). This indicates an anti-inflammatory effect of C646 on gene expression in RAW264.7 macrophages, as opposed to a pro-inflammatory effect of SAHA.
In order to move towards a more physiological environment, and towards a better model system for lung inflammation, we employed murine precision-cut lung slices (PCLS); 
LPS+IFNγ
Importantly, this indicates an anti-inflammatory effect of C646 on gene expression in PCLS.
For IL6 and KC, there were no changes in gene expression at the studied C646 concentrations (Table 1) . Upon pre-treatment of PCLS with SAHA as a reference compound at 0.41 μM, downregulation of the expression of iNOS induced by LPS and IFNγ was observed, whereas the expression of IL1β and IL6 were further enhanced ( Table 1) . No changes in expression of the other genes were found (Table 1) .
C646 increases histone acetylation on H3 residues 18-26
To assist the further development of C646 and potential derivatives towards applications for the treatment of inflammatory diseases, we proceeded to study changes in lysine acetylation in the cellular substrates of p300 upon C646 treatment. To this end, histone acetylation was quantified using a previously described mass spectrometry-based approach in which histones are acetylated on non-acetylated lysine residues using deuterated acetic acid anhydride ((CD 3 CO) 2 were observed ( Fig. 5 ), which is not in line with literature describing that p300 acetylates H4 at K5, K8, and K12 (25) . Furthermore, no changes in acetylation status of other histone H4 peptides were detected.
However, while analyzing histone H3, a difference in acetylation status for the peptide containing residues 18-26 was observed after 6 h of incubation with C646. Interestingly, a small yet significant increase in acetylation status was detected for this peptide containing H3 K18 and H3 K23 ( on acetylation status of this histone peptide. The HAT p300 has indeed been described to acetylate H3 K18 and K23 (25) , however, upon HAT inhibition a decrease in acetylation is to be expected instead of the observed increase. Thus, in this case, the observed effects on global histone acetylation are not in line with HAT inhibition. Using the mass spectrometry method, a wide range of acetylation sites was addressed in a single analysis giving an overview of the effect of C646 on histone acetylation (Fig. 6 ). . RAW264.7 cells were incubated with C646 at the indicated concentrations for 20 h, after which histones were extracted. Histones were resolved by SDS PAGE, and histones H3 and H4 were excised from the gels. Gel pieces were treated with acetic anhydride d6, followed by trypsin digestion. Resulting peptides were subjected to LC-MS/MS analysis. Data are presented as mean values ± SD of 2-12 independent experiments. No significant differences were observed between control and vehicle treated cells (data not shown). 
C646 inhibits recombinant HDACs
We set out to study the counterintuitive increase in histone acetylation upon C646 treatment in more detail. Based on the structural features of C646 ( Fig. 7) we hypothesized that its carboxylate might enable inhibition of HDACs at relatively high concentrations due to coordination of Zn 2+ in the active sites of HDACs, similar to HDACi such as sodium butyrate and sodium valproate (26) (Fig. 7) . In order to test the hypothesis that the p300
HATi C646 also inhibits HDACs, its inhibitory potency on recombinant HDACs 1-3, 6 and 8 was measured. In line with our hypothesis C646 indeed inhibited these HDACs (Table 2) , except for HDAC1, with potencies in the micromolar range. The observed selectivity profile for the investigated HDACs is interesting since the K i values for HDAC6 show the highest potency, whereas inhibition of HDAC1 is absent. To confirm that C646 is binding Zn 2+ , we looked closer into the kinetics of inhibition for the class I member HDAC2 and the class II member HDAC6. Unexpectedly, non-competitive inhibition was observed, with Boc-Lys-(Ac)-AMC as a substrate (Fig. 8 ). This is not in line with our hypothesis, and indicates either covalent or allosteric binding of C646 to these HDACs. Next to this, we also verified the HAT p300 inhibitory potency of C646 as reported by Bowers et al. (8) , and found comparable results with an IC 50 value of 0.32 μM. In addition, for the HAT KAT8 (hMOF), we found no inhibition by C646, which supports the previous findings that C646 is a p300 selective HATi ( HDACi contain distinct structural features as described for the marketed HDACi SAHA. They generally consist of a zinc binding group, a linker that occupies a relatively narrow tunnel, and a cap that binds to the solvent exposed surface of the enzyme. The carboxylate-based HDACi sodium butyrate and sodium valproate and the p300 HATi C646 contain carboxylate groups that could also coordinate to zinc in the HDAC active site. SAHA a --0.037 ± 0.005 0.09 ± 0.009 0.031 ± 0.009 0.034 ± 0.007 0.001 ± 0.0002 a: K i values for SAHA were determined at our lab previously (27) . b: This is an IC 50 value.
C646 decreases tubulin acetylation status
The highest potency for HDAC inhibition by C646 was observed for HDAC6. Therefore, we set out to investigate if HDAC6 inhibition observed for the recombinant enzyme is also reflected in inhibition of deacetylation of α-tubulin, which is a well-known cellular target of HDAC6 (28), in RAW264.7 cells. The α-tubulin acetylation status was monitored by immunoblotting using an anti-acetyl-α-tubulin antibody. After incubation with C646 for 6 h at 30 μM, but not at 15 μM, a pronounced inhibition of α-tubulin acetylation was observed ( Fig. 9A and B) , which is not in line with inhibition of HDAC6. The inhibition of α-tubulin acetylation was also observed after 20 h of incubation with C646 at 30 μM ( Fig. 9A and C) .
Treatment with the reference compound SAHA upregulated α-tubulin acetylation (data not shown).
Discussion
The inhibitory effects of C646 on pro-inflammatory gene expression in RAW264.7 macrophages and in murine precision-cut lung tissue slices upon receiving an LPS and IFNγ stimulus are promising for further development of this inhibitor in model systems of inflammatory lung diseases. The results suggest inhibition of NF-κB signaling, in line pre-treatment. This would support previous lines of research focusing on reducing NF-κB activity in inflammatory lung diseases (14) and indicate that this is a promising strategy. This is also in line with previous studies indicating inhibition of the NF-κB pathway upon C646 treatment in prostate cancer cells (10) , and decreased expression of the NF-κBmediated pro-inflammatory gene COX-2 upon C646 treatment in rats (9) . after pre-treatment with an HDACi. HDACi pre-treatments are done more often in studies with HATi to increase the detection window for inhibition of the acetyl transfer reaction.
For example, upon pre-treatment with HDACi trichostatin A (TSA) C646 demonstrated a pronounced inhibition of histone acetylation (31) (8).
In contrast, observations similar to ours that C646 increases histone acetylation have been made in a model system employing pancreatic cancer cells (24) , also after a short incubation time with C646 (4 h). The authors attributed the observed increase in histone H3 acetylation on K18 and K23 to increased cooperative binding of p300 to its substrate acetyl CoA, facilitated by C646 when present at low concentrations. The authors suggest that C646 can be outcompeted by acetyl CoA under these conditions. Although this model may explain the increased histone acetylation in cells at low concentrations of C646, it would be less suited to explain the increase observed in our system in which we employed relatively high concentrations of C646.
The observation that the p300 HATi C646 increases histone acetylation may also be explained through another mechanism. It has recently been reported that the overall histone acetylation levels remain remarkably constant upon depletion of HATs (32) .
In Drosophila cells, it was observed that histone acetylation levels were unaffected or in some cases even higher upon siRNA mediated knockdown of specific acetyltransferases. Based on the inhibitory potency of C646 for HDAC6, we monitored α-tubulin acetylation; an HDAC6 substrate. C646 treatment provided pronounced inhibition of α-tubulin acetylation after both 6 and 20 h of incubation, which argues against HDAC6 inhibition by C646 in RAW264.7 cells. The observed effect of C646 on α-tubulin acetylation may originate from inhibition of the HAT p300, which could directly reduce α-tubulin acetylation. However, p300 has not been described to acetylate α-tubulin directly.
Alternatively, the results can be explained by the following. p300 has been described to mediate acetylation of HDAC6, which renders this HDAC less active (35) (36) . Therefore, inhibition of p300 by C646 could decrease HDAC6 acetylation, thereby increasing HDAC6 activity, and thereby resulting in less α-tubulin acetylation.
In conclusion, this study indicates that C646 has potential for further development towards suppression of pro-inflammatory gene expression in inflammatory diseases such as asthma and COPD. However, instead of the expected inhibition of histone acetylation a slight increase was observed upon C646 treatment in RAW264.7 macrophages, which is corroborated by inhibition of HDAC activity in enzyme activity assays. It remains unclear if the suppression of pro-inflammatory gene expression is due to its HAT inhibitory activity, due to its HDAC inhibitory activity, or inhibition of other enzymes (or a combination of these factors). We anticipate that the balance between HAT and HDAC inhibition depends on the precise target lysine(s) for acetylation or deacetylation, the enzymes that regulate them, and the extent of inhibition of these enzymes by C646. Despite its potential to suppress pro-inflammatory gene transcription this study indicates that further optimization of this inhibitor with respect to its HDAC inhibitory potency, and to its HAT inhibitory selectivity over HDACs, is needed for further development.
Experimental Section
Chemicals and reagents
All chemicals and reagents were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands) unless otherwise stated. C646 was purchased from Axon Medchem (Groningen, the Netherlands) and SAHA from Selleckchem (Munich, Germany). The purity of C646 was assessed by HPLC, MS, and NMR by Axon Medchem, and the same was done for SAHA by Selleckchem.
Cell culture and viability assay RAW264.7 macrophages were purchased from American Type Culture Collection (Manassas, Virginia, USA), and cell culture reagents were purchased from Life Technologies (Bleiswijk, the Netherlands). RAW-Blue macrophages were purchased from InvivoGen (Toulouse, France). RAW264.7 macrophages were cultured as described previously (37) .
RAW-Blue macrophages were cultured in the same manner, with the addition of Zeocin (200 μg/mL) to the culture medium according to the manufacturer's instructions. For the experiments, cells were used until passage 18. Viability of C646 or HDACi SAHA treated RAW264.7 was assessed by CellTiter 96 Aqueous One Solution Cell Proliferation Assay (# G3581, Promega, Leiden, the Netherlands). For the assay, cells were seeded at 7500 cells per well in 96 wells plates. On the following day, medium was replaced with medium containing C646 or SAHA at the appropriate concentrations. After 20 h of incubation, the CellTiter reagent was added to the wells. After 1 h of incubation with this reagent, the absorbance at 490 nm was measured using a Synergy H1Hybrid Multi-Mode Microplate Reader (BioTek, Vermont, USA). The amount of absorbance at this wavelength is indicative of mitochondrial conversion of the reagent, which is linked to cell viability.
Precision-cut lung slices
Precision-cut lung slices (PCLS) were prepared as described previously (37) . All experiments were performed according to national guidelines and upon approval of the experimental procedures by the local Animal Care and Use committee of Groningen University, DEC number 6962A. Viability of C646 treated PCLS was assessed by the amount of lactate dehydrogenase (LDH) released by the tissue slices into the culture medium. The measurements were performed as described previously (37) . Viability of SAHA treated PCLS was not determined.
Treatment of RAW264.7, RAW-Blue and PCLS with inhibitors and LPS/IFNγ
Cells or PCLS were pre-treated with C646 at 1, 5, 10, 15, 20, 25 
RAW-Blue NF-κB reporter gene assay
RAW-Blue macrophages are derived from RAW264.7 macrophages by chromosomal integration of a secreted embryonic alkaline phosphatase (SEAP) reporter construct inducible by NF-κB, and were used to monitor NF-κB promoter activity. After treatment with the inhibitors as described above, cell supernatants were used to perform the NF-κB reporter gene assay according to the manufacturer's instructions. 
Gene expression analysis in RAW264.7 or PCLS by RT-q-PCR
Gene expression analysis by RT-q-PCR was performed as described previously (37) . The
GAPDH (Mm99999915_g1) were purchased as Assay-on-Demand (Applied Biosystems).
Enzyme inhibition assays and Lineweaver-Burk plots
All human recombinant HDAC inhibition assays were performed as described previously (27) . The Lineweaver-Burk plots of C646 on HDAC2 and HDAC6 were also performed as described previously (27) . Activity of the HAT MOF (KAT8) was measured using chemical detection of coenzyme A (CoASH) after fluorescent labelling as described previously (38) .
To test inhibition of the HAT p300 by C646, the following protocol was used. Histones were digested at 37 °C for 16 h. Supernatants containing histone peptides were subjected to LC MS/MS analysis as described below. were specified in Phenyx as variable modifications.
NanoChip LC-MS/MS QTOF
Immunoblot protocol
To study α-tubulin acetylation, 20 μg of cell lysate was loaded on a 10% polyacrylamide gel, resolved by SDS-PAGE electrophoresis and electroblotted to PVDF membranes. The membranes were incubated with anti-acetyl α-tubulin antibody (Cell Signalling # 5335) or with anti-GAPDH (Cell Signalling # 5174), followed by a swine anti-rabbit HRP conjugated antibody (DakoCytomation, P0217). Bands were visualized using a 1B1581 visiglo prime HRP chemiluminescence substrate kit from Amresco (Solon, Ohio, USA). Bands were scanned using a G:BOX iChemi system from Syngene (Cambridge, UK) and quantified using ImageJ quantification software (version 1.48d). The GAPDH signal was used as loading control. The experiments were performed at least in triplicate.
Statistical analysis
GraphPad Prism 5.0 or 4.0 software (GraphPad Software Inc., San Diego, CA, USA) was used to perform data analysis in all experiments. Data are presented as mean ± SD from at least 3 independent experiments, and were analyzed by 1-way analysis of variance, followed by Bonferroni post hoc tests unless otherwise stated. Significance was assigned at a p value ≤0.05.
